Allergan Plc (AGN)

166.10
0.54 0.33
NYSE : Health Technology
Prev Close 165.56
Open 165.65
Day Low/High 165.41 / 166.62
52 Wk Low/High 114.27 / 197.00
Volume 3.08M
Avg Volume 4.94M
Exchange NYSE
Shares Outstanding 328.03M
Market Cap 54.57B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.77%)

Latest News

Broadcom, WeWork, Dow Futures, China Trade, Cloudflare - 5 Things You Must Know

Broadcom, WeWork, Dow Futures, China Trade, Cloudflare - 5 Things You Must Know

U.S. stock futures rise as investors assess signs of a breakthrough in U.S.-China trade talks; Broadcom falls after saying chip demand has 'bottomed out'; WeWork will list its shares on the Nasdaq; Cloudflare's IPO is priced at $15 a share.

AbbVie Stock Rises After UBS Upgrades To Buy

AbbVie Stock Rises After UBS Upgrades To Buy

The $79 price target is a 14% upside to Wednesday's closing price.

Allergan Shareholder Meetings Scheduled For October 14, 2019

Allergan Shareholder Meetings Scheduled For October 14, 2019

DUBLIN, Sept. 10, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc...

Mike Holliday-Williams To Succeed Adrian Grace As CEO Of Aegon UK

Mike Holliday-Williams To Succeed Adrian Grace As CEO Of Aegon UK

Aegon today announces that Mike Holliday-Williams (1970, UK) will succeed Adrian Grace (1963, UK) as Chief Executive Officer of Aegon UK.

Mallinckrodt Plunges on Report It's Considering Filing for Bankruptcy

Mallinckrodt Plunges on Report It's Considering Filing for Bankruptcy

Shares of drugmaker Mallinckrodt plunge on a report the company is considering filing for bankruptcy as a way of dealing with its opioid-related legal liabilities.

Allergan Receives FDA Approval Of Juvéderm VOLUMA® XC For Mid-Face Injection Via Cannula

Allergan Receives FDA Approval Of Juvéderm VOLUMA® XC For Mid-Face Injection Via Cannula

DUBLIN, Sept. 3, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today it received U.

Allergan Reaches Settlement With Ohio Plaintiffs in Federal Opioid Litigation

Allergan Reaches Settlement With Ohio Plaintiffs in Federal Opioid Litigation

Allergan announces it has reached a settlement with two plaintiffs in Ohio in the multi-district federal litigation over opioids.

Allergan Announces Settlement With Two Ohio Plaintiffs In Federal Opioid Litigation

Allergan Announces Settlement With Two Ohio Plaintiffs In Federal Opioid Litigation

DUBLIN, Aug. 30, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the Company and its U.

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.

Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)

Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)

Study Evaluated Efficacy and Safety of ABP 798 Compared to Rituxan in Patients With Non-Hodgkin's Lymphoma

Endo Surges as Opioid Maker Reaches Settlement in Landmark Lawsuit

Endo Surges as Opioid Maker Reaches Settlement in Landmark Lawsuit

Endo's stock price surges after the company announces a settlement with Cuyahoga and Summit counties, removing the company from a potentially damaging trial in state court in October.

Endo, Allergan Nearing Deals to Limit Ohio Litigation Over Opioids - Report

Endo, Allergan Nearing Deals to Limit Ohio Litigation Over Opioids - Report

Allergan is said to be discussing paying $5 million while Endo is close to an agreement to pay $10 million, according to a report.

Aegon Reports First Half 2019 Results

Aegon Reports First Half 2019 Results

Net income increases to EUR 618 million reflecting realized gains and lower other charges ● Underlying earnings decrease by 5% to EUR 1,010 million, reflecting lower fee income as a result of lower average asset balances in the US, and investments in the...

Evolus Could See Breakout Soon

Evolus Could See Breakout Soon

EOLS appears to have formed a small triangle pattern the past few weeks and a breakout is likely before reaching the apex.

Lard Friese To Succeed Alex Wynaendts As Aegon's CEO

Lard Friese To Succeed Alex Wynaendts As Aegon's CEO

Aegon announces that its Supervisory Board intends to propose the appointment of Lard Friese as Chief Executive Officer to the Annual General Meeting of Shareholders.

AbbVie: The Right Mixture for the Perfect Stock

AbbVie: The Right Mixture for the Perfect Stock

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

The Dow ends up over 300 points on Tuesday, bouncing back one day after its worst session of the year so far.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal

Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal

Allergan posted stronger-than-expected second quarter earnings Tuesday, and re-affirmed its full-year profit guidance, after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie in late June.

Allergan Reports Second Quarter 2019 Financial Results

Allergan Reports Second Quarter 2019 Financial Results

- Q2 2019 GAAP Net Revenues of $4.09 Billion -

A Timeline of Botox's History

A Timeline of Botox's History

A timeline of how Botox became one of the most popular medical beauty procedures.

Dow Rebound?, Disney Reports, Barneys Files Chapter 11 - 5 Things You Must Know

Dow Rebound?, Disney Reports, Barneys Files Chapter 11 - 5 Things You Must Know

U.S. stock futures rise Tuesday, following Wall Street's worst day of the year, as China attempts to ease trade tensions with the U.S., Walt Disney to report earnings Tuesday; Barneys New York files for bankruptcy protection.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Disney, Uber, Lyft and More - Earnings to Watch in the Week Ahead

Disney, Uber, Lyft and More - Earnings to Watch in the Week Ahead

While you may think earnings season is winding down, we still got quite a bit left to go ... here are key companies to keep an eye on the week of August 5, 2019.

Aegon Completes Share Buyback Program

Aegon Completes Share Buyback Program

Aegon has completed the share buyback program announced on June 19, 2019. This program neutralized the dilutive effect of the 2018 final dividend paid in shares.

Allergan To Report Second Quarter 2019 Financial Results

Allergan To Report Second Quarter 2019 Financial Results

DUBLIN, Aug. 2, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release second quarter 2019 financial results on Tuesday, August 6, 2019, prior to the open of U.

Trump Just Deepened the Tariff War -- Retail Investors Were the Smart Ones

Trump Just Deepened the Tariff War -- Retail Investors Were the Smart Ones

Retail investors are sitting pretty after Trump enacted more tariffs. See their fancy footwork executed in July.

TheStreet Quant Rating: C (Hold)